Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius subsp. salicinius AP-32 metabolites + lactobacillus plantarum LPL28 metabolites + lactobacillus paracasei ET-66 metabolites
- Development stage
- Preclinical
- Lead developer
- Jinqi Biological
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PE0301 is a postbiotic formulation developed by Glac Biotech Co., Ltd., consisting of metabolites and inanimate bacterial cells from three specific lactic acid bacteria strains: *Lactobacillus salivarius* subsp. *salicinius* AP-32, *Lactobacillus paracasei* ET-66, and *Lactobacillus plantarum* LPL28. Unlike traditional probiotics, PE0301 is a '3-Mix fermentation postbiotic powder' (FPP) containing non-viable cells and a cell-free fermentation supernatant rich in lactic acid and polysaccharides. It is primarily designed to enhance oral health and salivary immunity by exhibiting antibacterial activity and stimulating the production of salivary immunoglobulin A (sIgA). Clinical studies have also demonstrated its ability to modulate the oral and gut microbiota, increasing levels of beneficial *Lactobacillus* and *Bifidobacterium* species, while providing gastroprotective effects in the upper gastrointestinal tract.
- Other names
- 3-Mix fermentation postbiotic powder3-Mix FPPPE0301PE-0301PE 0301
02
Targets
IgA (Immunoglobulin A)
Beyond the preview
Go deeper on lactobacillus salivarius subsp. salicinius AP-32 metabolites + lactobacillus plantarum LPL28 metabolites + lactobacillus paracasei ET-66 metabolites.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius subsp. salicinius AP-32 metabolites + lactobacillus plantarum LPL28 metabolites + lactobacillus paracasei ET-66 metabolites.